These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 3481507)
101. Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells. Marth C; Zeimet AG; Böck G; Daxenbichler G Eur J Cancer; 1992; 28A(12):2002-6. PubMed ID: 1419298 [TBL] [Abstract][Full Text] [Related]
102. Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patients. Ruibal A; Genollá J; Rosell M; Gris JM; Colomer R Int J Biol Markers; 1986; 1(3):159-60. PubMed ID: 3480917 [No Abstract] [Full Text] [Related]
103. CA-125 antigen in rhesus monkeys with spontaneous endometriosis. Pittaway DE; Klimek M; Koritnik DR Fertil Steril; 1986 Nov; 46(5):967-9. PubMed ID: 3465596 [No Abstract] [Full Text] [Related]
104. Screening for ovarian cancer by CA-125 measurement. Cruickshank DJ Lancet; 1988 Mar; 1(8584):540-1. PubMed ID: 2893964 [No Abstract] [Full Text] [Related]
105. Cross-reactivity of normal gastric tissue components with ovarian tumour-associated antigens. Dawson JR; Kutteh WH Br J Cancer; 1980 Sep; 42(3):481-4. PubMed ID: 6158974 [No Abstract] [Full Text] [Related]
107. Testosterone-producing ovarian tumor associated with erythrocytosis, hyperuricemia, and recurrent deep vein thrombosis. Muechler EK Am J Obstet Gynecol; 1977 Oct; 129(4):467-9. PubMed ID: 910832 [No Abstract] [Full Text] [Related]
108. [Modified E rosette test in patients with malignant ovarian neoplasms]. Simm S; Tomaszkiewicz T; Markowska J; Kominek P Ginekol Pol; 1981 Mar; 52(3):225-30. PubMed ID: 6973504 [No Abstract] [Full Text] [Related]
109. [Immunoenzyme study of interspecific embryonic antigens in the blood serum of ovarian cancer patients]. Chekhonin VP; Makarov OV; Tatarinov IuS; Griaznova IM Akush Ginekol (Mosk); 1987 Mar; (3):69-70. PubMed ID: 3296812 [No Abstract] [Full Text] [Related]
110. Digital necrosis and lupus-like syndrome preceding ovarian carcinoma. Chtourou M; Aubin F; Savariault I; Chabot P; Manchet G; Montcuquet P; Humbert P Dermatology; 1998; 196(3):348-9. PubMed ID: 9621147 [TBL] [Abstract][Full Text] [Related]
111. Circulating antigen levels in ovarian cancer. Colomer R; Genollà J; del Campo JM; Ruibal A J Clin Oncol; 1986 Jul; 4(7):1148-9. PubMed ID: 3723170 [No Abstract] [Full Text] [Related]
112. [Immunology of malignant ovarian tumors. I. Familial occurrence, antigens and specific immunity]. Markowska J Ginekol Pol; 1984 Sep; 55(9):695-700. PubMed ID: 6398791 [No Abstract] [Full Text] [Related]
113. [Value of a new tumor marker, CA 19-9, in primary bronchial cancers]. Vindimian M; Lafitte JJ; Duriez D; Wattre P Presse Med; 1984 Jul 14-21; 13(29):1787. PubMed ID: 6235511 [No Abstract] [Full Text] [Related]
114. On the 'human' nature of highly malignant heterotransplantable tumors of human origin. Goldenberg DM; Götz H Eur J Cancer (1965); 1968 Oct; 4(5):547-8. PubMed ID: 5760735 [No Abstract] [Full Text] [Related]